INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040.

INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilization and early embryo development to take place within a woman's body, offering a more natural and patient-centered alternative to traditional in vitro fertilization (IVF).

INVOcell was initially granted FDA clearance in 2015 and, in 2023, received additional FDA clearance for a labeling update that extended the recommended incubation period from three days to five days. The original INVOcell device design incorporated both a main chamber and a microchamber. Through years of real-world clinical use and feedback from practitioners, a simplified design featuring a single main chamber without a separate microchamber was designed. The Company subsequently submitted the modified design for patent protection which has now been granted.